JP2022533260A - タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 - Google Patents
タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 Download PDFInfo
- Publication number
- JP2022533260A JP2022533260A JP2021569449A JP2021569449A JP2022533260A JP 2022533260 A JP2022533260 A JP 2022533260A JP 2021569449 A JP2021569449 A JP 2021569449A JP 2021569449 A JP2021569449 A JP 2021569449A JP 2022533260 A JP2022533260 A JP 2022533260A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dioxopiperidine
- oxo
- optionally substituted
- thieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852844P | 2019-05-24 | 2019-05-24 | |
| US62/852,844 | 2019-05-24 | ||
| PCT/US2020/034264 WO2020242960A1 (en) | 2019-05-24 | 2020-05-22 | Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533260A true JP2022533260A (ja) | 2022-07-21 |
| JP2022533260A5 JP2022533260A5 (https=) | 2023-06-07 |
Family
ID=71092611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569449A Pending JP2022533260A (ja) | 2019-05-24 | 2020-05-22 | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11345712B2 (https=) |
| EP (1) | EP3976623A1 (https=) |
| JP (1) | JP2022533260A (https=) |
| KR (1) | KR20220023343A (https=) |
| CN (1) | CN114502543A (https=) |
| AU (1) | AU2020283744A1 (https=) |
| CA (1) | CA3140078C (https=) |
| EA (1) | EA202192910A1 (https=) |
| IL (1) | IL288204A (https=) |
| MX (1) | MX2021014345A (https=) |
| SG (1) | SG11202112355VA (https=) |
| TW (1) | TW202110818A (https=) |
| WO (1) | WO2020242960A1 (https=) |
| ZA (1) | ZA202109124B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| MX2022006133A (es) * | 2019-12-06 | 2022-06-17 | Celgene Corp | Procesos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin- 3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. |
| WO2021119571A1 (en) * | 2019-12-12 | 2021-06-17 | Biotheryx, Inc. | Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications |
| WO2021126973A1 (en) * | 2019-12-17 | 2021-06-24 | Orionis Biosciences, Inc. | Compounds modulating protein recruitment and/or degradation |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| JP2023545274A (ja) * | 2020-10-07 | 2023-10-27 | クルゲン（シャンハイ），インク． | 癌を処置する化合物および方法 |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN117203196A (zh) | 2020-12-14 | 2023-12-08 | 拜欧斯瑞克斯公司 | Pde4降解剂、药物组合物和治疗应用 |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| AU2022253450A1 (en) * | 2021-04-05 | 2023-11-16 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
| CA3221549A1 (en) * | 2021-06-08 | 2022-12-15 | Liqiang Fu | Isoindolinone compounds, and uses thereof |
| US20240368113A1 (en) * | 2021-06-28 | 2024-11-07 | Chengdu Fendi Pharmaceutical Co. Ltd. | Amide compound and use thereof |
| JP2024527628A (ja) * | 2021-07-19 | 2024-07-25 | メッドシャイン ディスカバリー インコーポレイテッド | ヘテロアリール－３－ピペリジンジオン化合物その使用 |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023070120A1 (en) * | 2021-10-22 | 2023-04-27 | Biotheryx, Inc. | Ketoamides for treating malignancy |
| WO2023069708A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and uses thereof |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| KR20240123836A (ko) * | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN114835680A (zh) * | 2022-04-29 | 2022-08-02 | 成都分迪药业有限公司 | 卤素取代异吲哚啉化合物及其应用 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| EP4584259A1 (en) * | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024167423A1 (en) * | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| WO2024222918A1 (zh) * | 2023-04-28 | 2024-10-31 | 中国药科大学 | 一种苯并六元杂环类gspt1蛋白降解剂及其应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525889A (ja) * | 2000-12-27 | 2004-08-26 | セルジーン・コーポレーション | イソインドール−イミド化合物、組成物、およびそれらの使用 |
| JP2010539206A (ja) * | 2007-09-19 | 2010-12-16 | ４エスツェー アクチェンゲゼルシャフト | 新規テトラヒドロ融合ピリジン |
| WO2017201069A1 (en) * | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| KR20170132934A (ko) * | 2016-05-24 | 2017-12-05 | 한국화학연구원 | Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| US20180170948A1 (en) * | 2016-12-21 | 2018-06-21 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| JP2019507114A (ja) * | 2016-01-08 | 2019-03-14 | セルジーン コーポレイション | 抗増殖化合物、ならびにそれらの薬学的組成物及び使用 |
| CA3063804A1 (en) * | 2017-05-22 | 2019-12-09 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof |
| JP2021520372A (ja) * | 2018-04-26 | 2021-08-19 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108069959A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
| US10406165B2 (en) | 2017-03-14 | 2019-09-10 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| CA3101338A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
| CA3106239A1 (en) * | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
-
2020
- 2020-05-22 JP JP2021569449A patent/JP2022533260A/ja active Pending
- 2020-05-22 TW TW109117256A patent/TW202110818A/zh unknown
- 2020-05-22 KR KR1020217039259A patent/KR20220023343A/ko not_active Withdrawn
- 2020-05-22 CN CN202080052899.5A patent/CN114502543A/zh active Pending
- 2020-05-22 SG SG11202112355VA patent/SG11202112355VA/en unknown
- 2020-05-22 EP EP20732707.3A patent/EP3976623A1/en not_active Withdrawn
- 2020-05-22 MX MX2021014345A patent/MX2021014345A/es unknown
- 2020-05-22 AU AU2020283744A patent/AU2020283744A1/en not_active Abandoned
- 2020-05-22 WO PCT/US2020/034264 patent/WO2020242960A1/en not_active Ceased
- 2020-05-22 EA EA202192910A patent/EA202192910A1/ru unknown
- 2020-05-22 CA CA3140078A patent/CA3140078C/en active Active
- 2020-05-26 US US16/882,750 patent/US11345712B2/en active Active
-
2021
- 2021-11-16 ZA ZA2021/09124A patent/ZA202109124B/en unknown
- 2021-11-17 IL IL288204A patent/IL288204A/en unknown
-
2022
- 2022-05-30 US US17/804,566 patent/US20220298172A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525889A (ja) * | 2000-12-27 | 2004-08-26 | セルジーン・コーポレーション | イソインドール−イミド化合物、組成物、およびそれらの使用 |
| JP2010539206A (ja) * | 2007-09-19 | 2010-12-16 | ４エスツェー アクチェンゲゼルシャフト | 新規テトラヒドロ融合ピリジン |
| JP2019507114A (ja) * | 2016-01-08 | 2019-03-14 | セルジーン コーポレイション | 抗増殖化合物、ならびにそれらの薬学的組成物及び使用 |
| WO2017201069A1 (en) * | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| KR20170132934A (ko) * | 2016-05-24 | 2017-12-05 | 한국화학연구원 | Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| US20180170948A1 (en) * | 2016-12-21 | 2018-06-21 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| CA3063804A1 (en) * | 2017-05-22 | 2019-12-09 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof |
| JP2021520372A (ja) * | 2018-04-26 | 2021-08-19 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EA202192910A1 (ru) | 2022-03-18 |
| MX2021014345A (es) | 2022-01-06 |
| ZA202109124B (en) | 2023-10-25 |
| CN114502543A (zh) | 2022-05-13 |
| US20200369679A1 (en) | 2020-11-26 |
| US11345712B2 (en) | 2022-05-31 |
| AU2020283744A1 (en) | 2021-12-09 |
| US20220298172A1 (en) | 2022-09-22 |
| TW202110818A (zh) | 2021-03-16 |
| IL288204A (en) | 2022-01-01 |
| KR20220023343A (ko) | 2022-03-02 |
| EP3976623A1 (en) | 2022-04-06 |
| CA3140078A1 (en) | 2020-12-03 |
| CA3140078C (en) | 2023-11-28 |
| WO2020242960A1 (en) | 2020-12-03 |
| SG11202112355VA (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11345712B2 (en) | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | |
| JP7050879B2 (ja) | ピラゾール化合物ならびにこの化合物を作製および使用するための方法 | |
| US12060367B2 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| US20240246954A1 (en) | Compositions and methods for inhibiting kras | |
| US9133187B2 (en) | Serine/threonine kinase inhibitors | |
| US10059705B2 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
| US20240408093A1 (en) | Heterobifunctional compounds and their use in treating disease | |
| US20250268925A1 (en) | Methods of treating medical conditions and inhibiting line1 reverse transcriptase using a substituted adeninyl-propyloxy phosphonic acid or related compound | |
| TWI716976B (zh) | 高活性sting蛋白激動劑 | |
| US20230227470A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| CN115427394A (zh) | 用于调节nr2f6的杂环化合物 | |
| WO2023011596A1 (zh) | 酰胺类化合物及其应用 | |
| CN117157290A (zh) | 用于抑制kras的组合物及方法 | |
| US11407831B2 (en) | Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230519 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230529 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240516 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240611 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20241203 |